To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

NCT ID: NCT00141336

Last Updated: 2007-01-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

750 participants

Study Classification

INTERVENTIONAL

Study Start Date

1999-11-30

Study Completion Date

2005-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the long-term safety and tolerability of pregabalin in patients with partial seizures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seizure Disorder, Partial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pregabalin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion Criteria

* Cannot have absence seizures
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Phoenix, Arizona, United States

Site Status

Pfizer Investigational Site

Tucson, Arizona, United States

Site Status

Pfizer Investigational Site

Bakersfield, California, United States

Site Status

Pfizer Investigational Site

Berkeley, California, United States

Site Status

Pfizer Investigational Site

Concord, California, United States

Site Status

Pfizer Investigational Site

Covina, California, United States

Site Status

Pfizer Investigational Site

El Cajon, California, United States

Site Status

Pfizer Investigational Site

Encino, California, United States

Site Status

Pfizer Investigational Site

La Mesa, California, United States

Site Status

Pfizer Investigational Site

Marina Del Ray, California, United States

Site Status

Pfizer Investigational Site

Martinez, California, United States

Site Status

Pfizer Investigational Site

Northridge, California, United States

Site Status

Pfizer Investigational Site

Pinole, California, United States

Site Status

Pfizer Investigational Site

Redondo Beach, California, United States

Site Status

Pfizer Investigational Site

Sacramento, California, United States

Site Status

Pfizer Investigational Site

Sacramento, California, United States

Site Status

Pfizer Investigational Site

San Diego, California, United States

Site Status

Pfizer Investigational Site

Santa Monica, California, United States

Site Status

Pfizer Investigational Site

Walnut Creek, California, United States

Site Status

Pfizer Investigational Site

Denver, Colorado, United States

Site Status

Pfizer Investigational Site

Englewood, Colorado, United States

Site Status

Pfizer Investigational Site

Danbury, Connecticut, United States

Site Status

Pfizer Investigational Site

Miami, Florida, United States

Site Status

Pfizer Investigational Site

Miami, Florida, United States

Site Status

Pfizer Investigational Site

Orlando, Florida, United States

Site Status

Pfizer Investigational Site

Tampa, Florida, United States

Site Status

Pfizer Investigational Site

Atlanta, Georgia, United States

Site Status

Pfizer Investigational Site

Chicago, Illinois, United States

Site Status

Pfizer Investigational Site

Chicago, Illinois, United States

Site Status

Pfizer Investigational Site

Chicago, Illinois, United States

Site Status

Pfizer Investigational Site

Crestview Hills, Kentucky, United States

Site Status

Pfizer Investigational Site

Louisville, Kentucky, United States

Site Status

Pfizer Investigational Site

Ruston, Louisiana, United States

Site Status

Pfizer Investigational Site

Baltimore, Maryland, United States

Site Status

Pfizer Investigational Site

Detroit, Michigan, United States

Site Status

Pfizer Investigational Site

Golden Valley, Minnesota, United States

Site Status

Pfizer Investigational Site

Minneapolis, Minnesota, United States

Site Status

Pfizer Investigational Site

Jackson, Mississippi, United States

Site Status

Pfizer Investigational Site

St Louis, Missouri, United States

Site Status

Pfizer Investigational Site

Las Vegas, Nevada, United States

Site Status

Pfizer Investigational Site

Las Vegas, Nevada, United States

Site Status

Pfizer Investigational Site

Concord, New Hampshire, United States

Site Status

Pfizer Investigational Site

Dover, New Hampshire, United States

Site Status

Pfizer Investigational Site

New Brunswick, New Jersey, United States

Site Status

Pfizer Investigational Site

New Brunswick, New Jersey, United States

Site Status

Pfizer Investigational Site

Ridgewood, New Jersey, United States

Site Status

Pfizer Investigational Site

Albuquerque, New Mexico, United States

Site Status

Pfizer Investigational Site

Albuquerque, New Mexico, United States

Site Status

Pfizer Investigational Site

Albuquerque, New Mexico, United States

Site Status

Pfizer Investigational Site

Brooklyn, New York, United States

Site Status

Pfizer Investigational Site

New York, New York, United States

Site Status

Pfizer Investigational Site

The Bronx, New York, United States

Site Status

Pfizer Investigational Site

Asheville, North Carolina, United States

Site Status

Pfizer Investigational Site

Asheville, North Carolina, United States

Site Status

Pfizer Investigational Site

Raleigh, North Carolina, United States

Site Status

Pfizer Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Pfizer Investigational Site

Winston-Salem, North Carolina, United States

Site Status

Pfizer Investigational Site

Cincinnati, Ohio, United States

Site Status

Pfizer Investigational Site

Cincinnati, Ohio, United States

Site Status

Pfizer Investigational Site

Columbus, Ohio, United States

Site Status

Pfizer Investigational Site

Oklahoma City, Oklahoma, United States

Site Status

Pfizer Investigational Site

Medford, Oregon, United States

Site Status

Pfizer Investigational Site

Portland, Oregon, United States

Site Status

Pfizer Investigational Site

Portland, Oregon, United States

Site Status

Pfizer Investigational Site

Portland, Oregon, United States

Site Status

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Pittsburgh, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Ridley Park, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Upland, Pennsylvania, United States

Site Status

Pfizer Investigational Site

Cranston, Rhode Island, United States

Site Status

Pfizer Investigational Site

Knoxville, Tennessee, United States

Site Status

Pfizer Investigational Site

Memphis, Tennessee, United States

Site Status

Pfizer Investigational Site

Dallas, Texas, United States

Site Status

Pfizer Investigational Site

Dallas, Texas, United States

Site Status

Pfizer Investigational Site

Dallas, Texas, United States

Site Status

Pfizer Investigational Site

Fort Worth, Texas, United States

Site Status

Pfizer Investigational Site

Fort Worth, Texas, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

Houston, Texas, United States

Site Status

Pfizer Investigational Site

Lubbock, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

San Antonio, Texas, United States

Site Status

Pfizer Investigational Site

Alexandria, Virginia, United States

Site Status

Pfizer Investigational Site

Alexandria, Virginia, United States

Site Status

Pfizer Investigational Site

Charlottesville, Virginia, United States

Site Status

Pfizer Investigational Site

Roanoke, Virginia, United States

Site Status

Pfizer Investigational Site

Roanoke, Virginia, United States

Site Status

Pfizer Investigational Site

Sterling, Virginia, United States

Site Status

Pfizer Investigational Site

Bellevue, Washington, United States

Site Status

Pfizer Investigational Site

Friday Harbor, Washington, United States

Site Status

Pfizer Investigational Site

Spokane, Washington, United States

Site Status

Pfizer Investigational Site

Spokane, Washington, United States

Site Status

Pfizer Investigational Site

Morgantown, West Virginia, United States

Site Status

Pfizer Investigational Site

Marshfield, Wisconsin, United States

Site Status

Pfizer Investigational Site

Milwaukee, Wisconsin, United States

Site Status

Pfizer Investigational Site

Calgary, Alberta, Canada

Site Status

Pfizer Investigational Site

Edmonton, Alberta, Canada

Site Status

Pfizer Investigational Site

Edmonton, Alberta, Canada

Site Status

Pfizer Investigational Site

Barrie, Ontario, Canada

Site Status

Pfizer Investigational Site

London, Ontario, Canada

Site Status

Pfizer Investigational Site

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1008-035

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pregabalin Epilepsy Add-On Trial
NCT00141258 COMPLETED PHASE3